Modulating innate immune activation states impacts the efficacy of specific A β immunotherapy

Passive immunotherapies targeting A β continue to be evaluated as Alzheimer’s disease (AD) therapeutics, but there remains debate over the mechanisms by which these immunotherapies work. Besides the amount of p...

Source: Molecular Neurodegeneration - May 6, 2021 Category: Neurology Authors: Yona Levites, Cory Funk, Xue Wang, Paramita Chakrabarty, Karen N. McFarland, Baxter Bramblett, Veronica O ’Neal, Xufei Liu, Thomas Ladd, Max Robinson, Mariet Allen, Minerva M. Carrasquillo, Dennis Dickson, Pedro Cruz, Danny Ryu, Hong-Dong Li & hellip; Tags: Research article Source Type: research